Abstract Langerhans cell histiocytosis (LCH) is a rare disease of antigen presenting cells, with an incidence rate of 4.0-5.4 per 1 million individuals. The most common endocrinological manifestation of classical LCH is associated with the posterior pituitary, presenting as Diabetes Insipidus. However, LCH can affect multiple organs and classification is based on the body system involvement. The disease is confirmed by electron microscopy or immunohistochemical reactivity of histiocytes to CD1a and/or S100. LCH rarely involves the thyroid gland, and management of such disease is controversial. Current literature documents 65 English language reported cases of LCH involving the thyroid gland. We present an unusual case of LCH of the thyroid gland, with variable diagnoses on fine needle aspiration (FNA) cytology, and literature review of all English reported cases.
Introduction
Langerhans cell histiocytosis (LCH) is a rare neoplastic disease of antigen presenting cells, with an incidence rate of 4.0-5.4 per 1 million individuals [1] . The most common endocrinological manifestation of classical LCH is associated with the posterior pituitary, presenting as Diabetes Insipidus (DI) [1] . However, LCH can affect multiple organs and classification is based on the body system involvement [2] . The disease is confirmed by electron microscopy (less commonly used today) or immunohistochemical reactivity of histiocytes to CD1a and/or S-100 protein [3] . LCH rarely involves the thyroid gland, and management of such disease is controversial. Current literature documents 65 English language reported cases of LCH involving the thyroid gland (Table 1) . We present an unusual case of LCH of the thyroid gland, with variable diagnoses on fine needle aspiration (FNA) cytology, and literature review of all English reported cases.
Case
A 44-year-old lady, with globus symptoms and dysphonia, presented to clinic with a 3-month history of a left-sided anterior neck swelling. Clinical examination revealed a firm painless left thyroid lobe and laryngoscopy did not identify any structural or functional abnormality of the vocal folds. The patient had no known drug allergies and was receiving levothyroxine hormone replacement therapy for (antibody negative) hypothyroidism. There was no additional past medical or surgical history.
An ultrasound scan (USS) of the neck, conducted at the referring hospital, reported an enlarged (3 cm in diameter) left thyroid lobe. Subsequent FNA cytology results 
Article in French
Panayotopoulos et al. [4] 11/M Diffusely enlarged firm goitre NR NR NR Wilkins [5] 8.5/F Firm goitre, dec T4, dec RAI uptake OM, DI Dessicated thyroid, pitressin NR Whitaker et al. [6] 19/M Goitre, (N) TSH, (N) T4, RAI uptake in right lobe only DI, skin, exertional dyspnoea ST NR Rothman et al. [7] 20/M Enlarged, smooth, diffuse goitre; suggested an epithelial neoplasm, with heavy eosinophilic infiltration, for which immunohistochemistry was negative for epithelial markers. Two months later, a second USS of the neck with FNA of the left thyroid lobe was performed which suggested medullary carcinoma. Blood tests revealed a normal full blood count, electrolytes, urea, creatinine, calcium, and phosphate levels. Thyroid function tests reported a thyroid stimulating hormone (TSH) level \0.01 l/L, Free T 4 of 15.7 pmol/L, and Free T 3 of 6.0 pmol/L (in keeping with treated hypothyroidism). In addition, serum calcitonin was recorded at \1.0 (normal range \ 11.8 ng/L) and urine catecholamine levels were within normal range.
Following discussion of the case at a multidisciplinary team meeting, a diagnostic left hemithyroidectomy was performed 2 months later. The left lobe of the thyroid appeared macroscopically abnormal and enlarged due to the infiltrating tumour, which extended to the region of the left recurrent laryngeal nerve (Fig. 1) . Due to the fact that there was no pre-operative diagnosis, and the left recurrent laryngeal nerve was not stimulating normally at 1 mA post left thyroid lobectomy, it was decided that the right thyroid lobe would not be removed at this stage.
Histologic examination revealed that the left thyroid lobe (12 g, and 4.5 9 3.5 9 2.0 cm) contained a circumscribed nodule composed of sheets and groups of round to ovoid cells with granular cytoplasm and vesicular grooved nuclei with numerous eosinophils (Fig. 2a-d) . Areas of lymphocytic infiltrate were also noted. The ovoid tumour cells were positive for CD1a, S-100 protein, and CD68 (KP1), but were negative for CAM5.2, TTF-1, CD38, and CD20.
All of the above findings are in keeping with LCH of the thyroid gland.
The patient made a good recovery and within 2 months following hospital discharge underwent a computer tomography (CT) scan of the neck, thorax, abdomen, and pelvis, which did not reveal any suspicious lesions. The patient remains disease-free at last follow-up 9 months later and is currently under close clinical surveillance.
Materials and Methods for Literature Review
The literature review was performed using the Pubmed database from 1961 to 2011. The term ''thyroid'' and keywords which have been referred to as LCH (e.g., 1. ''Histiocytosis X'', 2. ''Eosinophilic granuloma'', 3. ''Hand-Schuller-Christain disease'', 4. ''Letterer-Siwe disease'', 5. ''Langerhans cell (eosinophilic) granulomatosis'', 6. ''Type II histiocytosis'', 7. Hashimoto-Pritzker disease, 8. ''Self-healing histiocytosis'', 9. ''Pure cutaneous histiocytosis'', 10. ''Non-lipid reticuloendotheliosis''), were used [3, 67] . LCH may present as a tumour, skin rash, lytic bone lesions, pneumothorax, interstitial lung disease, central DI, or present with multiple affected organ systems within the human body [3] . Although posterior pituitary involvement is a common endocrinological presentation of LCH, manifestations of hypothalamic/pituitary axis disturbance and anterior pituitary deficiency, resulting in secondary or tertiary hypothyroidism, is less common [68] . LCH encompassed a group of conditions characterised by pathologic tissue infiltration with Langerhans cell granulomas [69] .
Langerhan cells (LCs), characterised by cytoplasmic rod-shaped organelles (Birbeck granules), are a type of dendritic cell and are classed as antigen presenting cells of the skin epidermis [70] . LCs express surface glycoproteins such as CD1a and Langerin (CD207), which are both related to the major histocompatibility complex Class 1 and 2. Following antigenic activation, LCs migrate to lymph Fig. 1 The thyroid bed after removal of the left thyroid lobe. The left recurrent laryngeal nerve can be seen surrounded by tumour prior to its laryngeal entry nodes where naïve T-cells are stimulated to secrete various cytokines such as granulocyte-macrophage stimulating factor (GM-CSF), interleukin-15 (IL-15), tumour necrosis factor-alpha (TNF-a), and tissue growth factor-beta (TGFb) for successful mounting of an immune response to the antigen in question [71] .
LCH cells are similar to LCs in that they possess Birbeck granules, microscopically, but differ in their shape; LCH cells are more rounded and lack dendritic extensions. At a molecular level, LCH cells express CD1a, Langerin (CD207), and S-100 protein, but do not express markers which are possessed by mature dendritic cells, such as CD83 [71] .
Although LCH has been considered to be a reactive process due to the lesions being composed of a mixture of eosinophils and lymphocytes with histiocytes, the latter cell type also exhibits monoclonality, which confirms that LCH is a neoplastic condition [72, 73] .
Solitary thyroid gland involvement with LCH is extremely rare with most cases presenting as part of multisystem disease (Table 1 ) [66] . Therefore, the frequency of solitary thyroid gland involvement is difficult to assess owing to the very few cases documented in medical literature. However, adults tend to be affected in greater numbers than children when assessing thyroid involvement of LCH (47 adult vs. 18 pediatric cases) ( Table 1) . Females have shown to be slightly more affected than males by a ratio of 1.4:1, respectively ( Table 2) .
LCH cases involving the thyroid gland present with diffuse (59%) or nodular thyroid (25.8%) enlargement (Table 2) . Thyroidal pain and obstructive symptoms secondary to a primary LCH goitre are rare [3] . In this case, the patient, who presented with a left-sided thyroid swelling, was experiencing dysphonia and globus symptoms owing to the infiltrative and compressive nature of the LCH tumour. A review of the literature has shown that thyroid hormone status in LCH involving the thyroid gland, may be variable, with cases being euthyroid (40.9%), hypothyroid (19.7%), and less commonly, subclinical hypothyroidism or hyperthyroidisim (10.6% vs. 1.5%, respectively) ( Table 2 ). In addition, antibodies such as antithyroglobulin and antimicrosomal antibodies have also been detected in cases of LCH involving the thyroid (Table 1) . Furthermore, 7.8% of cases show evidence of lymphocytic (Hashimoto's) thyroiditis. LCH involving the thyroid gland has been confused with many common entities, such as undifferentiated carcinoma, lymphoma, lymphocytic thyroiditis, chronic granulomatous thyroiditis, and cystic degeneration of multinodular goitre [3] . Therefore, considering primary thyroid LCH as a differential diagnosis is difficult owing to the variable clinical presentation of this condition.
Initial steps in the diagnosis of primary thyroid LCH involve investigations into the work-up of thyromegaly, namely, neck USS and FNA. Although FNA cytology may be useful in the diagnosis for thyroid LCH [19, 33] , this has shown to be variable with some cases being misdiagnosed as ''atypical follicular epithelial cells'' (as occurred in this case after the first FNA), and papillary or medullary carcinoma (as suggested in the second FNA performed in this [3] . Therefore, histology remains the most sensitive diagnostic modality, although there have been cases of histological misinterpretation of LCH (interpreted as poorly-differentiated carcinoma) [29, 30] . Once primary thyroid LCH has been diagnosed, it has been suggested that further investigations such as CT, bone scintigraphy, and abdominal USS may be performed to determine multisystem involvement [51] . The patient in this case underwent a whole body CT which was negative for suspicious lesions suggesting any extra-thyroidal manifestation of LCH. Treatment of choice for primary thyroid LCH is surgical resection by hemi -, subtotal, or total thyroidectomy [3, 51] . Of the 66 patients reviewed, 28 (42.4%) received surgery for thyroid involvement, 20 (30.3%) received surgery and adjuvant chemo-radiotherapy, and 12 (18.2%) received chemo-radiotherapy only ( Table 2 ). At present, there is no evidence to concretely demonstrate improved outcome with adjuvant chemo-radiotherapy for primary thyroid LCH postsurgical resection. However, bony and soft tissue disease with LCH have shown an 88% and 69% control rate, respectively, with control rates being higher in children as compared to adults (100% vs. 79%) [74] . Chemotherapy regimens with agents such as glucocorticoids, vinblastine, etoposide, cyclophosphamide, cyclohexylchloroethylnitrosurea (CCNU), methotrexate, doxorubicin and 2-Chlordeoxyadenosine (2-CdA) have been tried in disseminated or aggressive disease [75, 76] .
The overall mortality of LCH is 3%, compared with 15% in children [77] . When focussing on primary thyroid LCH, of the 66 cases reviewed, 24 (36.4%) reported no evidence of tumour post treatment (surgery ± chemoradiotherapy) with disease-free followup ranging from 3 months to 9 years. Additionally, in 7 cases (10.6%) patients died of disease. Interestingly, 2 cases (3%) were reported to be alive with disease. In 30 cases (45.5%), follow-up was not reported.
From our literature review, the majority of children had a combination of surgery and chemotherapy for treatment of thyroid LCH (52.6%), whereas the majority of adults had surgery alone (57.5%), followed by surgery and chemotherapy or radiotherapy (21.3%) ( Table 2) .
Conclusion
LCH is a rare disease, especially when the primary tumour originates from the thyroid gland. The mainstay of diagnosis of this rare condition is through histological analysis and immunohistochemical staining (S-100 protein, CD1a, Langerin). This article also highlights the variability of results obtained by FNA of the thyroid gland which may be misleading in the pre-operative diagnostic stages of LCH of the thyroid gland. Furthermore, the use of additional investigations, such as whole body CT, bone scintigraphy, and abdominal ultrasound, should be integrated within the investigative work-up protocol when LCH of the thyroid gland is diagnosed; this will allow for thorough investigation of extra-thyroidal LCH involvement. Although considered an inflammatory process, LCH is currently regarded as a low-grade malignancy and treatment remains mainly through local surgical resection with little evidence to suggest that adjuvant chemo-radiotherapy post thyroid resection provides a better outcome. Therefore, due to the lack of peer-reviewed articles on a treatment regimen for LCH of the thyroid gland, along with prolonged follow-up periods, studies assessing adjuvant and neo-adjuvant chemo-radiotherapy with local surgical resection with disease outcome data analysis are highly recommended.
